PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven primary or metastatic malignant supratentorial anaplastic
glioma

- Newly diagnosed or recurrent

- No diffusely infiltrating or multifocal tumor

- No tumor with subependymal spread

- Resection of glioma and placement of an intralesional catheter into the surgical
cavity required before study

- Measurable lesion on enhanced CT scan or MRI

- No measurable enhancing lesion greater than 1.0 cm beyond cavity margin

- Neoplastic cell reactivity with tenascin demonstrated by immunohistology with either
a polyclonal rabbit antibody or a monoclonal murine antibody

PATIENT CHARACTERISTICS:

Age:

- 3 and over

Performance status:

- Karnofsky 50-100%

Hematopoietic:

- Absolute neutrophil count greater than 1,000/mm^3

- Platelet count greater than 100,000/mm^3

Hepatic:

- Bilirubin less than 1.5 mg/dL

- AST less than 1.5 times normal

- Alkaline phosphatase less than 1.5 times normal

Renal:

- Creatinine less than 1.2 mg/dL

Other:

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- At least 6 weeks since prior chemotherapy unless unequivocal evidence of tumor
progression

Endocrine therapy:

- Corticosteroids allowed if at lowest possible dose and dose stable for at least 10
days prior to entry

Radiotherapy:

- At least 3 months since prior radiotherapy to site of measurable disease unless
unequivocal evidence of tumor progression

Surgery:

- See Disease Characteristics